JPMorgan Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $46.99 --0%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 15
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 15
Join SI Premium – FREE
JPMorgan analyst Jessica Fye downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $26.00 (from $19.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $22.97 yesterday.
You May Also Be Interested In
- Baird Downgrades Q2 Holdings (QTWO) to Neutral, 'Balanced Risk/ Reward'
- Finning International Inc. (FTT:CN) (FINGF) PT Raised to Cdn$44 at Scotiabank
- Nomura/Instinet Downgrades Yamato Kogyo Co Ltd (5444:JP) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
